Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SPIRONOLACTONE Cause Malignant neoplasm progression? 25 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Malignant neoplasm progression have been filed in association with SPIRONOLACTONE (spironolactone). This represents 0.1% of all adverse event reports for SPIRONOLACTONE.

25
Reports of Malignant neoplasm progression with SPIRONOLACTONE
0.1%
of all SPIRONOLACTONE reports
8
Deaths
16
Hospitalizations

How Dangerous Is Malignant neoplasm progression From SPIRONOLACTONE?

Of the 25 reports, 8 (32.0%) resulted in death, 16 (64.0%) required hospitalization, and 3 (12.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SPIRONOLACTONE. However, 25 reports have been filed with the FAERS database.

What Other Side Effects Does SPIRONOLACTONE Cause?

Acute kidney injury (3,273) Hyperkalaemia (2,518) Hypotension (1,583) Dyspnoea (1,468) Drug ineffective (1,379) Hyponatraemia (1,166) Dizziness (991) Fatigue (990) Fall (947) Off label use (899)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which SPIRONOLACTONE Alternatives Have Lower Malignant neoplasm progression Risk?

SPIRONOLACTONE vs SPRYCEL SPIRONOLACTONE vs STALEVO SPIRONOLACTONE vs STANNOUS FLUORIDE SPIRONOLACTONE vs STANOZOLOL SPIRONOLACTONE vs STAVUDINE

Related Pages

SPIRONOLACTONE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression SPIRONOLACTONE Demographics